Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
NTLA Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 20, 2026
Report Source: 2026 1st Quarter Report
Intellia Therapeutics Inc. Stock Analysis NTLA
United States Health Care Small Cap Report: Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 377 full-time employees. The company went IPO on 2016-05-06. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The firm is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. The company is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
Read More Intellia Therapeutics Inc (NTLA) Chart
Key Statistics of Intellia Therapeutics Inc (NTLA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$15.43Volume
4.88MP/E Ratio (TTM)
-52 Week Range
Market Cap
1.73BAvg. Volume
6.70MDividend Yield
-Financial Metrics & Statements of Intellia Therapeutics Inc (NTLA)
FAQ's for Intellia Therapeutics Inc (NTLA)
- According to Musaffa’s Shariah screening methodology, Intellia Therapeutics Inc (NTLA) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Intellia Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Intellia Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Intellia Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Intellia Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Intellia Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.